Executive Summary
MUSCAT GROUP has decisively executed a sweeping cleanup — divesting and exiting unprofitable businesses while writing off dead inventory — completing a strategic focus and consolidation of its brand portfolio. Management has characterized the prior fiscal year as "fully clearing the decks," and is now outlining a path to earnings recovery from next fiscal year onward built on three pillars: strengthening EC channels for niche-top cosmetics brands centered on Kanarabo, overseas expansion starting with the Middle East, and re-accelerating growth through M&A. Proceeds from the BtoB business divestiture and a healthier balance sheet will serve as the funding base for growth investments, and it is particularly noteworthy that management has explicitly stated that returning to operating profitability will mark the starting point of the new mid-term plan.
Message from the Company
We have fully cleared the decks. We want to convey that by executing this business model transformation and purging all negative factors, we have entered a renewed growth trajectory heading into the new mid-term plan.
Key Discussion Points
Accelerating Kanarabo PMI and Returning to the Niche-Top Strategy
Kanarabo's EC sales mix currently stands at only ~8%, but the company has set a target of 15–16% for the current fiscal year. Based on preliminary March figures, EC initiatives have progressed to the point of catching up with the initial budget assumptions, and PMI delays are largely expected to be resolved. The company has pivoted away from over-investing in trend-driven products, redirecting marketing spend toward competitively advantaged niche-top staple items such as eyebrow tints and the newly launched Fujiko "Keana Odamari! Cream." Strengthening drugstore channel sales efforts will also be pursued in 2H.
Portfolio Restructuring and Restoring Financial Soundness
The divestiture of a subsidiary (involved in vertical short-video marketing leveraging brand support business expertise) generated a gain on sale of affiliated company shares of JPY 652M. The company has also fully exited unprofitable brands (JUDIN (formerly RiLi), HICAT, etc.). Cash and equivalents total JPY 1,693M against interest-bearing debt of ~JPY 1,428M and net assets of ~JPY 1,629M. Borrowing capacity for M&A targeting operating income-accretive assets has been restored, and the company is now positioned to invest in EPS-accretive opportunities.
Concrete Plans for Overseas Expansion Starting with the Middle East
The company plans to launch its proprietary cosmetics brands in the Gulf states — Dubai, Abu Dhabi, and Saudi Arabia — starting around summer of the current fiscal year. The Halal certification process is already underway, and wholesale distribution routes to local offline retail are largely in place. Initial investment is capped at ~JPY 10M, with the priority being a sales-led expansion of retail placement. Partnerships with local marketing players are also being arranged.
Envalith's Perspectives
Q&A Highlights
- Q
What caused the decline in Kanarabo's variety store sell-through rate, and what are the remedial measures?
AThree factors were at play: declining in-store sales driven by the industry-wide shift to EC; an excessive rollout of competitively undifferentiated trend products whose development had been locked in prior to the acquisition; and the resulting dilution of marketing spend. The remedial plan involves clearing dead inventory, then concentrating marketing budget on niche-top staple items to restore store-level repurchase rates. Fujiko "Keana Odamari! Cream," launched in March, is performing well and establishing itself as a second pillar after eyebrow tints. Additionally, in 2H the company plans to intensify drugstore channel sales efforts, expanding into distribution channels with strong affinity for staple products.
- Q
What were the main drivers of the downward revision, and what is the impact on next fiscal year?
AThe primary drivers were a slowdown in 4Q sales activities related to preparation for the BtoB business divestiture, a 3-month delay in Kanarabo's EC-focused PMI, and an industry-wide slump in variety store sales. On top of that, dead inventory disposal and impairment charges on unprofitable brands were consolidated into the current fiscal year. However, Kanarabo's EC sales recovered to initial budget levels in March monthly data, and going forward, budgets can be constructed with higher conviction based on the assumption that PMI is complete.
- Q
What is the state of financial soundness and borrowing capacity for future M&A?
AAs of December 31, 2025: cash and equivalents of JPY 1,693M, interest-bearing debt of ~JPY 1,428M, and net assets of ~JPY 1,629M. Assuming a 2x net D/E ratio, ~JPY 2B in additional borrowing is theoretically available. However, until consolidated OPM reaches a sufficiently high level, a realistic approach would be to limit borrowing to acquisitions of clearly profit-accretive assets, similar to the Matsumura Shoten deal.
- Q
How has the competitive landscape for MOVE.eBike changed following type approval certification?
AMore competitors than expected have entered the market, but tightening of type approval regulations is driving uncertified operators out, creating a more favorable competitive environment at present. MOVE had designed and developed its products with certification in mind from the outset, and the strategy is to capture replacement demand before competitors can catch up on compliance. That said, the budget baseline assumes maintaining current market share, with any aggressive investment contingent on monitoring market developments.
- Q
What is the specific timeline and investment scale for the Middle East expansion?
AThe plan targets the Gulf states — Dubai, Abu Dhabi, and Saudi Arabia — with rollout commencing around summer of the current fiscal year. The Halal certification process is underway, and wholesale routes to offline retail in Dubai are largely secured. Initial investment is capped at ~JPY 10M, with the priority being a sales-led expansion of retail placement. Partnerships with local marketing players are also being arranged, and the plan is to scale marketing investment incrementally based on actual sales performance.
Envalith, Inc. ("Envalith") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and Envalith and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. Envalith has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by Envalith using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, Envalith and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. Envalith and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
Envalith and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
Envalith may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that Envalith is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to Envalith. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of Envalith is strictly prohibited.
- Use for Other Investment Products
Except where Envalith has provided prior written approval, the use of this report and the trademarks or trade names of Envalith or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.